Related Experiment Videos
Etanercept: An overview
Ben Goffe1, Jennifer Clay Cather
1Department of Dermatology, University of Washington, 515 Minor Avenue, Suite 200, Seattle, WA 98104, USA. docgoffe@msn.com
Journal of the American Academy of Dermatology
|August 2, 2003
Abstract:
Etanercept, a competitive inhibitor of TNF-alpha, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.